

THE WHITE HOUSE

WASHINGTON

FOR IMMEDIATE RELEASE
NOVEMBER 1, 1995

CONTACT: LISA CAPUTO
NEEL LATTIMORE
KAREN FINNEY
202-456-2960

FIRST LADY HILLARY RODHAM CLINTON AND RUSSIAN FIRST LADY NAINA YELTSIN TAKE ANOTHER STEP IN THEIR CONTINUING EFFORTS ON BEHALF OF RUSSIAN CHILDREN

WASHINGTON, DC -- On behalf of First Lady Hillary Rodham Clinton, U. S. Ambassador to Russia Thomas Pickering and Jeffrey Lack, Vice President, CIS for the American company Bristol-Myers Squibb, yesterday presented \$350,000 worth of Phenyl-Free to Mrs. Naina Yeltsin and Dr. Vladimir Kocherovets, Deputy Minister of Health to the Russian Federation, at a reception in Moscow. "I am grateful to Bristol-Myers Squibb for donating this medicine, which will make a real difference in the lives of Russian children," said First Lady Hillary Rodham Clinton.

Phenyl-Free is a nutritional formula used to treat children suffering from Phenylketonuria (PKU), an inherited disease that affects the central nervous system in children. Diet therapy such as Phenyl-Free is the only known method of treatment.

In addition to the donated medicine, Bristol-Myers Squibb will sponsor an educational exchange on the diagnosis and treatment of PKU disease. Two Russian physicians, Dr. Alexander Baikov, head of the Moscow and Russian Centers for Neonatal Screening, and Dr. Anna Khatunova, the PKU specialist for the Ministry of Health of the Russian Federation, will visit Georgetown University Medical Center in Washington, DC later this year. Dr. Owen Rennart, Chairman of Pediatrics at Georgetown University Children's Medical Center, will travel to Russia to conduct a symposium for 20 Russian PKU specialists in early 1996.

The initiative originated during a visit to the United States by President and Mrs. Yeltsin in the fall of 1994. Mrs. Clinton invited Mrs. Yeltsin and Dr. Kocherovets to visit Georgetown University Children's Medical Center and participate in a roundtable discussion with American doctors and health care professionals to discuss children's health issues in the U.S. and in Russia. During the visit, Mrs. Yeltsin discussed with Mrs. Clinton the many problems associated with PKU disease and treatment in Russia. Following the visit, Mrs. Clinton convened a meeting with executives from Bristol-Myers Squibb and Dr. Rennart to discuss ways to respond to Mrs. Yeltsin's concerns.

Bristol-Myers Squibb estimates that the donated medicine will care for 125 children for one year.

###



Bristol-Myers Squibb Company

345 Park Avenue New York, NY 10154-0037 212 546-4343 Fax 212 605-9606

Jonathan Weisberg
Director
International Public Affairs

October 30, 1995
from: Jon Weisberg
to: Karen Finney

Ms. Finney:

David Keaney asked me to fax the following draft press release. I will call your office as soon as it is transmitted.

FOR IMMEDIATE RELEASE

MRS. YELTSIN ACCEPTS GIFT FROM MRS. CLINTON FOR THE CHILDREN OF RUSSIA
Special Infant Formula From Bristol-Myers Squibb Treats Inherited PKU Disease in Babies

MOSCOW, RUSSIA (October 31, 1995) - At a reception in Moscow today, Mrs. Naina Yeltsin accepted a donation of lifesaving nutritional diet therapy for Russian children born with phenylketonuria (PKU), an inherited disease which, if untreated, can lead to damage to the central nervous system and retardation. The donation of Phenyl-Free, made by Bristol-Myers Squibb Company on behalf of First Lady, Mrs. Hillary Rodham Clinton, will care for approximately 125 children for one year.

About xx Russian children are born with PKU each year. Nutritional therapy is the only treatment, and Mead Johnson Nutritionals, a Bristol-Myers Squibb company is the major manufacturer of products used to treat PKU. The value of the donated product is \$350,000 (U.S.).

During the reception, Mr. Thomas R. Pickering, U.S. Ambassador to Russia, presented the gift to Mrs. Yeltsin and Dr. Kocherovets, Deputy Minister of Health of the Russian Federation.

"Children are the future of Russia. Through this donation, Bristol-Myers Squibb Company hopes to make the future of children with PKU disease healthier, happier and more productive," said Mr. Jeffrey Lack, vice president, CIS, Bristol-Myers Squibb Company.

In addition to the 16,200 cans of free product, Bristol-Myers Squibb will sponsor an educational exchange on the diagnosis and treatment of PKU disease. Initially, two leading Russian physicians, Dr. A. Balkov, head of the Moscow and Russian Centers for Neonatal Screening and Dr. Khatunova, the PKU specialist for the Ministry of Health of the Russian Federation, will visit Georgetown University, in Washington, D.C. This will be followed by a visit to Russia by Dr. Owen Rennart of Georgetown University, to conduct a symposium for 20 regional Russian specialists.

The donation of Phenyl-Free and sponsorship of the educational exchange program is the culmination of efforts which began in 1994 when Mrs. Yeltsin accompanied her husband on a state visit to the U.S. At that time, during a visit by Mrs. Clinton, Mrs. Yeltsin and Dr. Kocherovets to Georgetown University Children's Hospital, Mrs. Yeltsin stressed the serious PKU disease problem in Russia. In response, Mrs. Clinton met with Bristol-Myers Squibb executives to seek a solution. The donation of Phenyl-Free and sponsorship of the educational exchange, resulted.

Bristol-Myers Squibb has worked closely with the Russian Ministry of Health and the Russian health care system for more than twenty years. In May 1992, the company, in conjunction with Akrihin, opened a modern manufacturing facility in Kupavna, Moscow Region, to produce cardiovascular medicines. This facility was the first factory in Russia authorized to make pharmaceuticals in compliance with the U.S. Food and Drug Administration's Good Manufacturing Practices.

Mead Johnson Nutritionals makes Phenyl Free, Phenyl Free High Protein and Lofenalac for the treatment of PKU disease. The company, a division of Bristol-Myers Squibb Company, also makes Enfamil, ProSobee and other infant formulas under the Russian

government "Children of Russia" program. Bristol-Myers Squibb also works with several Russian institutes and hospitals in the research and development of cardiovascular, oncological, central nervous system and anti-infective medicines.

Bristol-Myers Squibb Company is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer. The company is also a leader in consumer medicines, orthopaedic devices, ostomy care, wound management, nutritional supplements infant formulas, and hair and skin care products.